Literature DB >> 1122677

Pharmacological activity, metabolism, and pharmacokinetics of glycinexylidide.

J M Strong, D E Mayfield, A J Atkinson, B C Burris, F Raymon, L T Webster.   

Abstract

Glycinexylidide (GX) is a metabolite of lidocaine that is frequently present in mug/ml concentrations in the plasma of patients treated with lidocaine infusions for 24 hr or more. Plasma levels of GX have 26% the antiarrhythmic activity of lidocaine in an animal model, and GX adversely affects the mental performance of normal subjects at plasma concentrations comparable to those found in patients. The total volume of GX distribution in man is similar to that of lidocaine but the plasma clearance is less, so that the 10-hr elimination phase half-life of GX is much longer than the 1 1/2 hr half-life reported in normal subjects for lidocaine. About half of an administered dose of GX is excreted unchanged in urine, roughly 15% appears in urine as conjugates of xylidine and p-OH xylidine, and the fate of the rest is unknown.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1122677     DOI: 10.1002/cpt1975172184

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  16 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Drug kinetics and artificial kidneys.

Authors:  T B Gibson; H A Nelson
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

Review 3.  Effect of active drug metabolites on plasma level-response correlations.

Authors:  A J Atkinson; J M Strong
Journal:  J Pharmacokinet Biopharm       Date:  1977-04

Review 4.  Poisoning due to class 1B antiarrhythmic drugs. Lignocaine, mexiletine and tocainide.

Authors:  C P Denaro; N L Benowitz
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Nov-Dec

5.  The pharmacokinetics and pharmacodynamics of lignocaine and MEGX in healthy subjects.

Authors:  A H Thomson; H L Elliott; A W Kelman; P A Meredith; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1987-04

Review 6.  Clinical pharmacokinetics of lignocaine.

Authors:  N L Benowitz; W Meister
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

Review 7.  Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure.

Authors:  D E Drayer
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

Review 8.  Pharmacokinetics in patients with cardiac failure.

Authors:  N L Benowitz; W Meister
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

9.  An enzyme-distributed system for lidocaine metabolism in the perfused rat liver preparation.

Authors:  K S Pang; J A Terrell; S D Nelson; K F Feuer; M J Clements; L Endrenyi
Journal:  J Pharmacokinet Biopharm       Date:  1986-04

Review 10.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.